研究单位：[1]The Second Affiliated Hospital of Chongqing Medical University[2]Jiangsu Hansoh Pharmaceutical Co., Ltd.[3]The Second Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China,400010[4]Chongqing University Three Gorges Central Hospital,Chongqing,China,400010[5]Affiliated Hospital of Guangxi Medical University,Guangxi,China[6]Guizhou Provincial People's Hospital,Guiyang,China[7]Hepatobiliary disease of Jilin Province,Jilin,China[8]The First People's Hospital of Yunnan Province,Kunming,China[9]the Second People's Hospital of Yunnan Province,Kunming,China[10]Nanjing Second Hospital,Nanjing,China[11]The Second Hospital of Ningbo,Ningbo,China[12]Shanghai East Hospital,Shanghai,China[13]Shuguang Hospital, Shanghai, China.,Shanghai,China[14]The Sixth People's Hospital of Shenyang,Shenyang,China[15]Shijiazhuang Fifth Hospital,Shijiazhuang,China[16]The First People's Hospital of Taicang,Taicang,China[17]The Fourth People's Hospital of Zibo,Zibo,China
The goal of this observational study is to explore the efficacy and safety of Tenofovir Amibufenamide (TMF) in Entecavir (ETV) treated chronic hepatitis B patients with low-level viraemia. The main question it aims to answer is: - The efficacy and safety of TMF in chronic hepatitis B patients with low-level viraemia. - What is the appropriate treatment for ETV treated chronic hepatitis B patients with low-level viraemia. Participants will choose to maintain their original regimen (ETV) or switch to TMF After being fully informed of the benefits and risks of treatment. Researchers will compare ETV and TMF to see if there is a difference in the efficacy of the two drugs in chronic hepatitis B patients with low-level viraemia.
